tasidotin
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2003 (NCT00068211)
Timeline
2000s
- Jan 1, 2003
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- TubulinINHIBITOR
Tubulin inhibitor
- Tubulin beta-4B chain (TUBB4B) ↗
- Tubulin beta-1 chain (TUBB1) ↗
- Tubulin alpha-3C chain (TUBA3C) ↗
- Tubulin alpha-4A chain (TUBA4A) ↗
- Tubulin beta-3 chain (TUBB3) ↗
- Tubulin alpha-1A chain (TUBA1A) ↗
- Tubulin beta-4A chain (TUBB4A) ↗
- Tubulin beta-8 chain (TUBB8) ↗
- Tubulin beta chain (TUBB) ↗
- Tubulin alpha-1B chain (TUBA1B) ↗
- Tubulin alpha-1C chain (TUBA1C) ↗
- Tubulin alpha-3E chain (TUBA3E) ↗
- Tubulin beta-2A chain (TUBB2A) ↗
- Tubulin beta-2B chain (TUBB2B) ↗
- Tubulin beta-6 chain (TUBB6) ↗
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)[C@H](NC(=O)[C@H](C(C)C)N(C)C)C(=O)N(C)[C@H](C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)NC(C)(C)C)C(C)C- Mol. weight
- 606.85 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2111109 ↗
- ChEMBLCHEMBL2107376 ↗
Also known as
- bsf223651
- bsf 223651
- bsf-223651
- ilx651
- ilx651
- ilx651
- ilx651
- ilx 651
- ilx-651
- lu223651
- lu 223651
- lu-223651
- syn-d cpd
- synthadotin
- tasidotin
- tasidotin
- tasidotin
- tasidotin hcl
- tasidotin hcl
- tasidotin hydrochloride
- tasidotin hydrochloride
- tasidotin hydrochloride
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00082134 | Phase 2 | Apr 29, 2004 | Genzyme |
| NCT00078455 | Phase 2 | Dec 1, 2003 | Genzyme |
| NCT00068211 | Phase 2 | Aug 1, 2003 | Genzyme |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Genzyme | For profit | 3 | 3 | 1 | 2003 |
1 organizations
Page 1 / 1